In addition to the fact that some hypoglycaemic agents can accumulate in case of severe renal failure (e.g. sulfonylureas [16]), other non-hypoglycaemic GLT agents are preferable, such as DPP4-inhibitors, the safety of which (with adjusted doses for some) has been studied in case of severe renal impairment even in older patients [10, 17]. The gene discussed is DPP4; the disease is Renal insufficiency.